ABSTRACT
A market registration for a new drug can only be received if the efficacy and safety of the new compound has been tested and verified during clinical studies. Bringing a new drug to market requires the performance of clinical studies phases I-III to show with a high statistical safety an advantage for the new compound in comparison to already marketed drugs.
